Skip to main content

Remote Job Finders (RJF)

An Early-Career Stand Proved This Young Biotech Exec Had What It Takes

Ensho Therapeutics CEO Neena Bitritto-Garg, recently named to BioSpace’s 40 Under 40, proved her mettle managing one of the toughest partnerships out there: the one between Eisai and Biogen that led to new Alzheimer’s drugs Aduhelm and Leqembi.

BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates

Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives on the company’s investor call faced questions about a sluggish uptake for schizophrenia drug Cobenfy as well as a highly anticipated Alzheimer’s psychosis readout for the product.
Scroll to top